FHTX Foghorn Therapeutics Inc
Price (delayed)
$3.42
Market cap
$190.19M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$170.16M
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The
Highlights
Foghorn Therapeutics's EPS has increased by 32% YoY and by 18% from the previous quarter
The company's debt fell by 18% YoY and by 5% QoQ
The equity has plunged by 61% from the previous quarter but it has grown by 41% YoY
FHTX's gross profit is down by 34% year-on-year and by 11% since the previous quarter
The company's revenue fell by 34% YoY and by 11% QoQ
Key stats
What are the main financial stats of FHTX
Market
Valuations
Earnings
Shares outstanding
55.61M
Market cap
$190.19M
Enterprise value
$170.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.53
Revenue
$22.6M
Gross profit
$22.6M
Operating income
-$102.68M
Net income
-$86.62M
EBIT
-$86.62M
EBITDA
-$77.82M
Free cash flow
-$101.31M
Per share
Balance sheet
Liquidity
EPS
-$1.58
EPS diluted
-$1.58
Free cash flow per share
-$1.85
Book value per share
-$0.82
Revenue per share
$0.41
TBVPS
$5.17
Total assets
$283.98M
Total liabilities
$329.51M
Debt
$37.13M
Equity
-$45.53M
Working capital
$182.61M
Debt to equity
-0.82
Current ratio
3.73
Quick ratio
3.66
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
-344.3%
Gross margin
100%
Net margin
-383.2%
Operating margin
-454.3%
Return on assets
-29.5%
Return on equity
N/A
Return on invested capital
-44.9%
Return on capital employed
-39.9%
Return on sales
-383.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FHTX stock price
How has the Foghorn Therapeutics stock price performed over time
Intraday
1.33%
1 week
-10.24%
1 month
-29.48%
1 year
-51.14%
YTD
-27.54%
QTD
-6.3%
Financial performance
How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$22.6M
Gross profit
$22.6M
Operating income
-$102.68M
Net income
-$86.62M
Gross margin
100%
Net margin
-383.2%
FHTX's operating margin is down by 44% YoY and by 11% QoQ
FHTX's gross profit is down by 34% year-on-year and by 11% since the previous quarter
The company's revenue fell by 34% YoY and by 11% QoQ
The company's net margin fell by 33% YoY and by 7% QoQ
Growth
What is Foghorn Therapeutics's growth rate over time
Valuation
What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
8.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.53
Foghorn Therapeutics's EPS has increased by 32% YoY and by 18% from the previous quarter
The equity has plunged by 61% from the previous quarter but it has grown by 41% YoY
FHTX's P/S is 96% lower than its 5-year quarterly average of 185.6 and 36% lower than its last 4 quarters average of 12.8
The company's revenue fell by 34% YoY and by 11% QoQ
Efficiency
How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has decreased by 39% YoY and by 10% from the previous quarter
FHTX's return on invested capital is down by 21% year-on-year but it is up by 3.9% since the previous quarter
The ROA has grown by 4.8% from the previous quarter
Dividends
What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FHTX.
Financial health
How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 14% lower than its total liabilities
FHTX's quick ratio is down by 23% since the previous quarter and by 9% year-on-year
The current ratio has contracted by 22% from the previous quarter and by 9% YoY
The company's debt is 182% higher than its equity
The equity has plunged by 61% from the previous quarter but it has grown by 41% YoY
The debt to equity is down by 41% YoY but it is up by 41% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.